Bakteriophagentherapie: Grundlagen, Evidenz und klinische Anwendungsmöglichkeiten

Antimikrobielle Resistenzen nehmen weltweit zu und Infektionen durch resistente Erreger sind aufgrund eingeschränkter Therapieoptionen oft mit erhöhter Morbidität und Mortalität assoziiert. Die Bakteriophagentherapie (kurz: Phagentherapie) ist eine vielversprechende Alternative oder ergänzende Behandlungsstrategie zu traditionellen Antibiotika, da antibiotikaresistente Bakterien oft sensitiv gegenüber der Lyse durch Phagen sind.

Schlüsselwörter

Antibiotikaresistenz - bakterielle Infektion - Bakteriophagen - Phagen - individueller Heilversuch

Publikationsverlauf

Artikel online veröffentlicht:
17. August 2022

• Literatur

• 1 Murray CJL, Ikuta KS, Sharara F. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399: 629-655
• 2 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2021 Zugriff am 13. Mai 2022 unter: https://www.who.int/publications/i/item/9789240021303
• 3 Sausset R, Petit MA, Gaboriau-Routhiau V. et al. New insights into intestinal phages. Mucosal Immunology 2020; 13: 205-215 DOI: 10.1038/s41385-019-0250-5. (PMID: 31907364)
• 4 Gordillo Altamirano FL, Barr JJ. Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev 2019; 32: e00066-18 DOI: 10.1128/CMR.00066-18. (PMID: 30651225)
• 5 Luong T, Salabarria AC, Roach DR. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?. Clin Ther 2020; 42: 1659-1680 DOI: 10.1016/j.clinthera.2020.07.014. (PMID: 32883528)
• 6 Segall AM, Roach DR, Strathdee SA. Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr Opin Microbiol 2019; 51: 46-50 DOI: 10.1016/j.mib.2019.03.005. (PMID: 31226502)
• 7 Chan BK, Sistrom M, Wertz JE. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016; 6: 26717 DOI: 10.1038/srep26717. (PMID: 27225966)
• 8 Schooley RT, Biswas B, Gill JJ. et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother 2017; 61: e00954-17 DOI: 10.1128/AAC.00954-17. (PMID: 28807909)
• 9 LaVergne S, Hamilton T, Biswas B. et al. Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection. Open Forum Infect Dis 2018; 5: ofy064 DOI: 10.1093/ofid/ofy064. (PMID: 29687015)
• 10 Lebeaux D, Merabishvili M, Caudron E. et al. A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses 2021; 13: 60 DOI: 10.3390/v13010060. (PMID: 33466377)
• 11 Genevière J, McCallin S, Huttner A. et al. A systematic review of phage therapy applied to bone and joint infections: an analysis of success rates, treatment modalities and safety. EFORT Open Rev 2021; 6: 1148-1156 DOI: 10.1302/2058-5241.6.210073. (PMID: 35003759)
• 12 Rubalskii E, Ruemke S, Salmoukas C. et al. Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics (Basel) 2020; 9: 232 DOI: 10.3390/antibiotics9050232. (PMID: 32380707)
• 13 Paul K, Merabishvili M, Hazan R. et al. Bacteriophage Rescue Therapy of a Vancomycin-Resistant Enterococcus faecium Infection in a One-Year-Old Child following a Third Liver Transplantation. Viruses 2021; 13: 1785 DOI: 10.3390/v13091785. (PMID: 34578366)
• 14 Steele A, Stacey HJ, de Soir S. et al. The Safety and Efficacy of Phage Therapy for Superficial Bacterial Infections: A Systematic Review. Antibiotics (Basel) 2020; 9: 754 DOI: 10.3390/antibiotics9110754. (PMID: 33138253)
• 15 Leitner L, Ujmajuridze A, Chanishvili N. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis 2021; 21: 427-436 DOI: 10.1016/S1473-3099(20)30330-3. (PMID: 32949500)
• 16 Sarker SA, Sultana S, Reuteler G. et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine 2016; 4: 124-137 DOI: 10.1016/j.ebiom.2015.12.023. (PMID: 26981577)
• 17 Wright A, Hawkins CH, Anggård EE. et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34: 349-357 DOI: 10.1111/j.1749-4486.2009.01973.x. (PMID: 19673983)
• 18 Jault P, Leclerc T, Jennes S. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 2019; 19: 35-45 DOI: 10.1016/S1473-3099(18)30482-1. (PMID: 30292481)
• 19 Pirnay JP, Verbeken G, Ceyssens PJ. et al. The Magistral Phage. Viruses 2018; 10: 64 DOI: 10.3390/v10020064. (PMID: 29415431)
• 20 Duyvejonck H, Merabishvili M, Vaneechoutte M. et al. Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. Viruses 2021; 13: 865 DOI: 10.3390/v13050865. (PMID: 34066841)
• 21 Verbeken G, Pirnay JP. European regulatory aspects of phage therapy: magistral phage preparations. Curr Opin Virol 2021; 52: 24-29 DOI: 10.1016/j.coviro.2021.11.005. (PMID: 34801778)
• 22 WMA Declaration of Helsinki – Ethical principles for medical reseearch involving human subjects. Helsinki, Finland: 18th World Medical Association General Assembly; 1964
• 23 Cobián Güemes AG, Youle M, Cantú VA. et al. Viruses as Winners in the Game of Life. Annu Rev Virol 2016; 3: 197-214 DOI: 10.1146/annurev-virology-100114-054952. (PMID: 27741409)
• 24 Philipson CW, Voegtly LJ, Lueder MR. et al. Characterizing Phage Genomes for Therapeutic Applications. Viruses 2018; 10: 188 DOI: 10.3390/v10040188. (PMID: 29642590)